COVID-19 | Regulatory Guidelines Review

Global Health Authorities have introduced guidelines for clinical trials due to COVID-19. GXP Engaged invite you to access our review of approx. 60 of these guidelines covering aspects affected by the pandemic such as the provision of IMP/Supplies to subjects, Subject Visits, Informed Consent, Monitoring & Remote SDV, Sponsor Risk Assessments, Protocol Deviations & Amendments, Safety Reporting etc.

We warmly welcome feedback, additions, updates, suggestions for improvement in our review/interpretation.

GXP Engaged would like to add the disclaimer that the information on the spreadsheet is provided according to our review and interpretation of the guidance documents. Some documents do not give clear guidance and some text is open to interpretation. We discourage the taking of any specific action solely on the basis of the results presented. The original guidance document should always be consulted, or clarification sought from the relevant authority.

If you agree, we use cookies to integrate external services and media. Further information can be found in our data protection policy.

Please select what kind of cookies should be allowed to be set by confirming with "Accept selected" or accept all cookies by confirming with "Accept all":

Loading this resource will connect to external servers which use cookies and other tracking technologies to personalize and improve experience. Further information can be found in our privacy policy.

Allow external media